Postprostatectomy adjuvant versus salvage radiotherapy: A complication-adjusted number-needed-to-treat analysis

Cancer

Volumn 103, Issue 9, 2005, Pages 1833-1842

  Jani, Ashesh B ^a,b   Kao, Johnny ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Number needed to treat; Prostate carcinoma; Prostatectomy; Radiotherapy

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; DISEASE SEVERITY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION INJURY; REVIEW; SEXUAL DYSFUNCTION; STATISTICAL ANALYSIS; UROGENITAL TRACT DISEASE;

HUMANS; MALE; MODELS, THEORETICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17644426658     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20949     Document Type: Review

References (53)

1. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859-864.
2. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1048-1053.
3. Anscher MS. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer. 2001;96:91-93.
4. Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology. 1999;54:495-502.
5. Schild SE. Radiation therapy (RT) after prostatectomy: the case for salvage therapy as opposed to adjuvant therapy. Int J Cancer. 2001;96:94-98.
6. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
7. Bolla M, Van Poppel H, Van Cangh P, et al. Does postoperative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in T3N0 prostate cancer (PC)? [abstract]. Proc Am Soc Clin Oncol. 2004;23:382.
8. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol. 1999;17:1155-1163.
9. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
10. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
11. Cordell DL. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433-436.
12. Labbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
13. Riegelman R, Schroth WS. Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms. Med Decis Making. 1993;13:247-252.
14. Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure': number needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol. 1996;25:704-712.
15. Jani AB, Myrianthopoulos L, Vijayakumar S. The application of number needed to treat (NNT) to clinical problems in radiotherapy. Cancer Invest. 2004;22:262-270.
16. Abdalla I, Basu A, Hellman S. An evidence-based analysis of the management of localized prostate cancer. Cancer J. 2002;8:40-46.
17. Jani AB, Basu A, Heimann R, Hellman S. Sentinel node versus axillary node dissection for early stage breast cancer: a comparison using a utility-adjusted NNT (number needed to treat) analysis. Cancer. 2003;97:359-366.
18. Jani AB, Kao J, Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer. 2003;98:2351-2361.
19. Jani AB, Sokoloff M, Shalhav A, Stadler W. Androgen ablation adjuvant to post-prostatectomy radiotherapy: a complication-adjusted number-needed to treat analysis. Urology. 2004;64:976-981.
20. Tsien C, Griffith KA, Sandler HM, et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology. 2003;62:93-98.
21. Do LV, Do TM, Smith R, Parker RG. Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am J Clin Oncol. 2002;25:1-8.
22. Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59:51-60.
23. Valicenti RK, Gomella LG, Ismail M, et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology. 1998;52:1034-1040.
24. Peschel RE, Robnett TJ, Hesse D, et al. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int J Cancer. 2000;90:29-36.
25. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology. 1999;54:1049-1057.
26. Vicini FA, Ziaja EL, Kestin LL, et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999;54:111-117.
27. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol. 1994;151:1575-1578.
28. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:755-763.
29. Kalapurakal JA, Huang CF, Neriamparampil MM, et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002;54:1047-1054.
30. Mayer R, Pummer K, Quehenberger F, Mayer E, Fink L, Hackl A. Postprostatectomy radiotherapy for high-risk prostate cancer. Urology. 2002;59:732-739.
31. Morris MM, Dallow KC, Zietman AL, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:731-736.
32. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62:866-871.
33. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
34. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th edition. New York: Springer-Verlag, 2002.
35. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997;49:65-70.
36. Duchesne GM, Dowling C, Frydenberg M, et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology. 2003;61:179-183.
37. Maier J, Forman J, Tekyi-Mensah S, Bolton S, Patel R, Pontes JE. Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol. 2004;22:50-56.
38. Choo R, Hruby G, Hong J, et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys. 2002;52:674-680.
39. Petrovich Z, Lieskovsky G, Langholz B, et al. Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol. 1999;22:323-331.
40. Petrovich Z, Lieskovsky G, Langholz B, et al. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1998;40:139-147.
41. Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39:327-333.
42. Jani AB, Blend MJ, Hamilton R, et al. Radioimmunoscintigraphy for post-prostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004;45:1315-1322.
43. Van Cangh PJ, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol. 1998;159:164-166.
44. Cozzarini C, Fiorino C, Ceresoli GL, et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys. 2003;55:688-694.
45. Bastasch MD, Teh BS, Mai WY, et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Radiat Oncol Biol Phys. 2002;54:101-106.
46. Teh BS, Mai WY, Augspurger ME, et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:465-472.
47. Formenti SC, Lieskovsky G, Skinner D, Tsao-Wei DD, Groshen S, Petrovich Z. Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy. Urology. 2000;56:453-458.
48. Syndikus I, Pickles T, Kostashuk E, Sullivan LD. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol. 1996;155:1983-1986.
49. Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology. 1997;49:207-216.
50. Jani AB, Roeske JC, Rash C. Intensity modulated radiotherapy (IMRT) for prostate cancer. Clin Prostate Cancer. 2003;2:98-105.
51. Jani AB, Speibring D, Hamilton R, et al. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med. 2004;45:238-246.
52. Jani AB, Blend MJ, Hamilton R, et al. Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004;45:571-578.
53. Feldstein ML. Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on TWiST and Q-TWiST. Cancer. 1991;67(3 Suppl.):851-854.